Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin A for persistent post-traumatic headache
2024-515901-24-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic post-traumatic headache (CPTHA) comparing Botulinum toxin A with Placebo (2 arms). Primary endpoint: Responder rate at weeks 5 to 8. Planned start Oct 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
chronic post-traumatic headache (CPTHA)
Beyond the preview
Go deeper on 2024-515901-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515901-24-00.